Nadolol (Corgard)

A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.

Also Known As:

Networked: 352 relevant articles (50 outcomes, 49 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Chen, Wen-Chi: 5 articles (11/2012 - 03/2004)
2.	Lo, Gin-Ho: 5 articles (11/2012 - 03/2004)
3.	Wang, Huay-Min: 3 articles (11/2012 - 10/2006)
4.	Villanueva, C: 3 articles (08/2009 - 08/2001)
5.	Hsu, Ping-I: 3 articles (08/2008 - 03/2004)
6.	Lai, Kwok-Hung: 3 articles (08/2008 - 03/2004)
7.	Merkel, C: 3 articles (09/2005 - 02/2000)
8.	Gatta, A: 3 articles (09/2005 - 02/2000)
9.	Bolognesi, M: 3 articles (09/2005 - 02/2000)
10.	Sacerdoti, D: 3 articles (09/2005 - 02/2000)

Related Diseases

1.	Hemorrhage 03/01/2005 - "The aim of this study was to compare the efficacy of EVL combined with nadolol versus EVL alone as secondary prophylaxis for variceal bleeding. " 08/01/1988 - "The percentage of patients free of gastrointestinal bleeding 1 year after inclusion in the study was 83 +/- 6% (mean +/- S.D.) in the nadolol group and 80 +/- 6% in the placebo group. " 01/01/1988 - "Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study." 07/01/2010 - "Esophageal variceal bleeding occurred in 10 patients (14%) in the Combined group and nine patients (13%) in the Nadolol group (P = NS). " 07/01/2010 - "During a median follow-up of 26 months, 18 patients (26%) in the Combined group and 13 patients (18%) in the Nadolol group experienced upper gastrointestinal bleeding (P = NS). "
2.	Hypertension (High Blood Pressure) 01/01/1980 - "Both beta-blocking agents were effective in controlling hypertension with final daily doses ranging from 80 to 320 mg. Of statistical significance, however, were the better responses of supine systolic blood pressure elicited by nadolol. " 07/01/1980 - "Nevertheless, nadolol is one of a few beta-blocking drugs which have clearly been shown to be effective in both hypertension and angina with once daily administration. " 10/01/1984 - "Nadolol is safe and effective for the long-term treatment of both hypertension and angina. " 01/01/1982 - "A once-daily dose of nadolol combined with HCZ appears to be safe and effective therapy for the long-term treatment of mild or moderate essential hypertension." 10/01/1984 - "The efficacy of nadolol in hypertension and angina was maintained over the 2-year period. "
3.	Migraine Disorders (Migraine) 12/01/1984 - "Nadolol and placebo comparison study in the prophylactic treatment of migraine." 04/01/1982 - "Nadolol and placebo comparison study in the prophylactic treatment of migraine." 07/15/1984 - "[Nadolol in the preventive treatment of migraine]." 01/01/1983 - "Nadolol: its use in the prophylactic treatment of migraine." 03/01/2012 - "Both flunarizine and nadolol proved to be effective in the preventive treatment of episodic migraine. "
4.	Supraventricular Tachycardia 03/01/1992 - "Once a day nadolol is a safe and effective agent in the management of supraventricular tachycardia in children. " 11/01/1983 - "To assess antiarrhythmic efficacy of oral nadolol, 15 patients with recurrent supraventricular tachycardia were studied. " 08/31/1987 - "In a double-blind, placebo-controlled, parallel trial of intravenous nadolol in the treatment of sustained supraventricular tachycardia (SVT), 29 patients (20 men, 9 women) were studied. " 11/01/1983 - "Nadolol and supraventricular tachycardia: an electrophysiologic study." 11/01/1992 - "The pharmacokinetics of intravenous and oral nadolol, a long-acting beta-adrenoceptor blocking agent, were investigated in six children receiving the drug for treatment of supraventricular tachycardia. "
5.	Tachycardia (Tachyarrhythmias) 01/01/1985 - "Predictably both doses of nadolol produced significant reduction in exercise tachycardia which was still apparent at 24 h. " 03/01/1992 - "Intravenous nadolol was given to seven patients during electrophysiologic study; five of these had an excellent response and two had a partial response (25% decrease in tachycardia rate). " 08/01/1994 - "3. Nadolol produced dose-related reductions in exercise tachycardia in keeping with increasing beta 1-adrenoceptor blockade; mean % reduction (95% CI) compared with placebo: N5 10.7 (6.6 to 14.8), N20 21.4 (17.3 to 25.4), N80 38.9 (34.8 to 42.9). " 12/01/1989 - "It is suggested that the lack of a rise in the number of beta-receptors during exercise may contribute to the blunted exercise-induced tachycardia in patients taking nadolol." 08/31/1987 - "Intravenous nadolol also prevented induction of SVT in 2 of 17 (11%) patients with atrioventricular reentrant tachycardia. "

Related Drugs and Biologics

1.	Propranolol (Inderal)
2.	Atenolol (Tenormin)
3.	isosorbide-5-mononitrate (Ismo)
4.	Timolol (Blocadren)
5.	Metoprolol (Lopressor)
6.	Sotalol (Sotalol Hydrochloride)
7.	Digoxin (Digitek)
8.	Verapamil (Calan)
9.	Bendroflumethiazide (Naturetin)
10.	Bisoprolol (Concor)

Related Therapies and Procedures

1.	Ligation
2.	Sclerotherapy
3.	Vagus Nerve Stimulation
4.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
5.	Adrenalectomy